New hope for kids with severe bowel disease: testing a daily pill
NCT ID NCT07470879
Summary
This study is testing a daily oral medication called etrasimod in children aged 2 to 12 who have moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease. The main goal is to see if the drug is safe, effective at controlling the disease, and how it behaves in a child's body over a 52-week treatment period, with an option to continue for up to 5 years total. It is an open-label study, meaning all participants will receive the study drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Japanese Red Cross Kumamoto Hospital
Kumamoto, 861-8520, Japan
-
Juntendo University Hospital
Bunkyo-ku, Tokyo, 113-8431, Japan
-
Saitama Prefectural Children's Medical Center
Saitama-shi, Saitama, 330-8777, Japan
Conditions
Explore the condition pages connected to this study.